The Value of Digital Biomarkers in Clinical Trials

In recent years, the integration of digital biomarkers into clinical trials has garnered significant attention. Digital biomarkers are objective, quantifiable physiological and behavioral data collected and measured by digital devices such as wearables, portables, and implantables. These biomarkers offer a promising avenue for enhancing the efficiency and accuracy of clinical trials. This article explores the value digital biomarkers bring to clinical trials and identifies specific biomarkers that have shown substantial promise. 

The Role of Digital Biomarkers in Clinical Trials 

Digital biomarkers provide several advantages over traditional clinical outcome assessments (COAs). They offer continuous monitoring, real-time data collection, and improved participant engagement. These features are particularly valuable in clinical trials, where accurate and timely data collection is crucial for assessing the efficacy and safety of investigational treatments. 

One of the primary benefits of digital biomarkers is their potential to offer more objective evidence and improve signal detection. Trials in many areas of neuroscience, including psychiatry often suffer from high placebo response rates and low drug-placebo separation due to factors such as misdiagnosis, enrollment pressures, and subjective assessments. Digital biomarkers may prove to be vital tools to addressing these longstanding issues. 

Types of Digital Biomarkers 

Several types of digital biomarkers have been identified as valuable in clinical trials. These include vocal biomarkers, facial expression analysis, movement biomarkers, and physiological measures. 

• Vocal Biomarkers: Vocal biomarkers analyze speech patterns, including speech latency, tone, and other vocal features. These biomarkers have shown promise in psychiatric and neurological clinical trials ¹. For example, speech latency variables have been used to enrich participant selection in depression studies, enhancing the primary outcome effect size². Vocal biomarkers can also identify data quality issues and duplicate subjects, improving the overall quality of the trial data. 
• Facial Expression Analysis: Facial expressions can reveal significant insights into psychiatric and neurological conditions. AI-powered facial expression analysis can extract, analyze, and interpret complex behavioral and physiological signals, providing a rich source of objective, quantifiable data ³. This technology is particularly useful in early detection and proactive intervention for conditions such as schizophrenia, dementia, and anxiety disorders. 
• Movement Biomarkers: Movement biomarkers assess motor function and human behavior through wearable devices. These biomarkers are valuable in trials for conditions such as Parkinson’s disease and other neurological disorders. They provide continuous monitoring and real-time data, allowing for a more comprehensive assessment of treatment efficacy. 
• Physiological Measures: Physiological biomarkers include heart rate, blood pressure, and other vital signs measured through wearable devices. These biomarkers offer continuous monitoring and can provide early indicators of treatment efficacy and safety. They are particularly useful in trials for cardiovascular and metabolic disorders. 

Case Examples 

• Depression and Schizophrenia Trials: In a recent depression study, the incorporation of speech latency variables enabled an enrichment strategy for participant selection. The results were startling, enhancing the primary outcome effect size by 52%². This indicates that speech latency is an objective marker of depression, schizophrenia, and other psychiatric conditions that can feasibly be used for enrichment. Additionally, a follow-up study demonstrated similar results using a modification of the same speech latency measure, showing dramatic improvements in signal detection for schizophrenia⁴. Taken together, these findings support our understanding of speech latency as an objective marker in psychiatric conditions. 
• Parkinson’s Disease Trials: Movement biomarkers have been extensively used in Parkinson’s disease trials. Wearable devices that monitor motor function provide continuous data on tremors, gait, and other motor symptoms. This real-time data collection allows for a more accurate assessment of treatment efficacy and can identify subtle changes in motor function that may not be captured through traditional assessments. 
• Cardiovascular Trials: Physiological biomarkers such as heart rate and blood pressure are critical in cardiovascular trials. Wearable devices that continuously monitor these vital signs provide early indicators of treatment efficacy and safety. This continuous monitoring can detect adverse events earlier, allowing for timely intervention and improving patient safety. 

Challenges and Considerations 

While digital biomarkers offer significant advantages, there are also challenges and considerations to address. One of the primary challenges is the validation and standardization of digital biomarkers. Ensuring that these biomarkers are reliable, reproducible, and clinically meaningful is crucial for their successful integration into clinical trials. 

Another consideration is the potential for data overload. Digital biomarkers generate vast amounts of data, which can be overwhelming to analyze and interpret. Advanced data analytics and machine learning algorithms are essential for extracting meaningful insights from this data. 

Additionally, there are ethical and privacy concerns related to the use of digital biomarkers. Ensuring that patient data is securely collected, stored, and used is paramount. Clear guidelines and regulations are needed to address these concerns and protect patient privacy. 

Future Directions 

The future of digital biomarkers in clinical trials looks promising. Advances in artificial intelligence and machine learning will continue to enhance the accuracy and reliability of digital biomarkers. New, low-burden approaches to the assessment of clinically relevant features of speech, motor function, and human behavior are expected to emerge. 

Moreover, the integration of digital biomarkers with other digital health technologies, such as telemedicine and remote monitoring, will further improve patient engagement and trial efficiency. The use of digital biomarkers in decentralized and hybrid clinical trials is also expected to increase, providing more flexibility and convenience for participants. 

Conclusion 

Digital biomarkers offer substantial value in clinical trials by providing objective, continuous, and real-time data. They enhance the accuracy and efficiency of trials, reduce placebo response, and improve patient engagement. Vocal biomarkers, facial expression analysis, movement biomarkers, and physiological measures are among the most promising digital biomarkers in clinical trials. While there are challenges to address, the future of digital biomarkers in clinical trials looks bright, with continued advancements in technology and data analytics paving the way for more effective and efficient clinical research. 

---

References 

1. Cohen, A., Rodriguez, Z., Opler, M., Kirkpatrick, B., Milanovic, S., Piacentino, D., Szabo, S. T., Tomioka, S., Ogirala, A., Koblan, K. S., Siegel, J. S., Hopkins, S. Evaluating speech latencies during structured psychiatric interviews as an automated objective measure of psychomotor slowing. Psychiatry Res. 2024 Oct; 340:116104.

2. Siegel, J., Cohen, A., Szabo, S., Tomioka, S., Opler. M., Kirkpatrick, B., Hopkins, S. (2024). Enrichment using speech latencies improves treatment effect size in a clinical trial of bipolar depression. Journal of Psychiatry Research, 340, 5. https://www.sciencedirect.com/science/article/abs/pii/S0165178124003901   

3. Cowan, T., Rodriguez, Z. B., Strauss, G. P., Raugh, I. M., Cohen, A.S. Eur Arch Psychiatry Clin Neurosci. 2024 Oct;274(7):1771-1775.

4. Cohen, A., Kirkpatrick, B., Opler, M., Sedway, J., Tatsumi, K., Bhat, S., Bhat, L. Enrichment based on speech latency enhances treatment effects in a phase III study of brilaroxazine. Poster., 2024 Nov.